Email updates

Keep up to date with the latest news and content from Experimental Hematology and Oncology and BioMed Central.

Open Access Letter to the Editor

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy

Ashley Jeter1 and Yubin Kang12*

Author Affiliations

1 Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA

2 Hollings Cancer Center, 86 Jonathan Lucas Street, Room# HO307, Charleston, SC, 29425, USA

For all author emails, please log on.

Experimental Hematology & Oncology 2012, 1:20  doi:10.1186/2162-3619-1-20

Published: 15 August 2012


Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation. However, occasionally bortezomib-induced neuropathy can be severe and affects motor and/or autonomic nerves, and may be mediated by immune process. The role of immune modulation therapy in the management of bortezomib-induced PN was not well established. Here, we reported a case of bortezomib-induced severe PN that responded well to plasma exchange and steroid treatment.

Bortezomib; Peripheral neuropathy; Immune modulation; Multiple myeloma